Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Palomo L, Meggendorfer M, Hutter S, et al. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood. 2020;136(16):1851–1862.
   PubMed Web of Science ®Google Scholar
• Hochman MJ, Bipin SN, Jain T. Examining disease boundaries: genetics of myelodysplastic/myeloproliferative neoplasms. eJHaem. 2021;2(3):607–615.
   PubMedGoogle Scholar
• Sharma P, Shinde SS, Damlaj M, et al. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leuk Lymphoma. 2017;58(4):872–881.
   PubMed Web of Science ®Google Scholar
• Kongtim P, Popat U, Jimenez A, et al. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2016;22(1):47–53.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413–418.
   PubMed Web of Science ®Google Scholar
• Mangaonkar AA, Swoboda DM, Coltro G, et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020;34(2):656–661.
   PubMed Web of Science ®Google Scholar
• Meldi K, Qin T, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015;125(5):1857–1872.
   PubMed Web of Science ®Google Scholar
• Minařík L, Pimková K, Kokavec J, et al. Analysis of 5-azacytidine resistance models reveals a set of targetable pathways. Cells. 2022 Jan 11;11(2):223.
   Google Scholar
• Savona MR, Malcovati L, Komrokji R, MDS/MPN International Working Group, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125(12):1857–1865.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Gondek LP, Varadhan R, et al. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Br J Haematol. 2021;193(6):1142–1150.
   PubMed Web of Science ®Google Scholar
• Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94:767–779.
   PubMed Web of Science ®Google Scholar
• Duchmann M, Braun T, Micol JB, et al. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Blood Cancer J. 2017;7(5):e562.
   PubMedGoogle Scholar
• Al-Kali A, Abou Hussein AK, Patnaik M, et al. Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. Leuk Lymphoma. 2018;59(11):2737–2739.
   PubMed Web of Science ®Google Scholar
• Elena C, Gallì A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408–1417.
   PubMed Web of Science ®Google Scholar
• Duchmann M, Yalniz FF, Sanna A, et al. Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents. EBioMedicine. 2018;31:174–181.
   PubMed Web of Science ®Google Scholar
• Unnikrishnan A, Papaemmanuil E, Beck D, et al. Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017;20(3):572–585.
   PubMed Web of Science ®Google Scholar
• Leung KK, Nguyen A, Shi T, et al. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome. Proc Natl Acad Sci USA. 2019;116(2):695–700.
   PubMed Web of Science ®Google Scholar
• Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9):1852–1860.
   PubMed Web of Science ®Google Scholar
• Inoue D, Kitaura J, Matsui H, et al. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia. 2015;29(4):847–857.
   PubMed Web of Science ®Google Scholar
• Falconi G, Fabiani E, Piciocchi A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia. 2019;33(3):785–790.
   PubMed Web of Science ®Google Scholar
• Carratt SA, Braun TP, Coblentz C, et al. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia. 2021;35(12):3594–3599.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Hematology Am Soc Hematol Educ Program. 2020;2020(1):450–459.
   PubMedGoogle Scholar
• Wu P, Weng J, Li M, et al. Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs. Am J Transl Res. 2019;11(6):3651–3658.
   PubMed Web of Science ®Google Scholar
• Rinke J, Müller JP, Blaess MF, et al. Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms. Leukemia. 2017;31(9):1936–1943.
   PubMed Web of Science ®Google Scholar
• Gawlitza AL, Speith J, Rinke J, et al. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. J Cancer Res Clin Oncol. 2019;145(11):2835–2843.
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12.
   PubMed Web of Science ®Google Scholar